Literature DB >> 24667170

Polo-like kinase-1 in DNA damage response.

Sun-Yi Hyun1, Hyo-In Hwang, Hyo-In Hwan1, Young-Joo Jang1.   

Abstract

Polo-like kinase-1 (Plk1) belongs to a family of serine-threonine kinases and plays a critical role in mitotic progression. Plk1 involves in the initiation of mitosis, centrosome maturation, bipolar spindle formation, and cytokinesis, well-reported as traditional functions of Plk1. In this review, we discuss the role of Plk1 during DNA damage response beyond the functions in mitotsis. When DNA is damaged in cells under various stress conditions, the checkpoint mechanism is activated to allow cells to have enough time for repair. When damage is repaired, cells progress continuously their division, which is called checkpoint recovery. If damage is too severe to repair, cells undergo apoptotic pathway. If damage is not completely repaired, cells undergo a process called checkpoint adaptation, and resume cell division cycle with damaged DNA. Plk1 targets and regulates many key factors in the process of damage response, and we deal with these subjects in this review.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24667170      PMCID: PMC4163859          DOI: 10.5483/bmbrep.2014.47.5.061

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


INTRODUCTION: BRIEF ON PLK1

The first polo-like kinase (Plk) was primarily discovered in polo gene of Drosophila melanogaster and functional mutation of this gene has various defects in mitosis (1,2). This polo gene has highly conserved from yeast to human and functions as a key regulator during mitosis, meiosis and cytokinesis (3). Plk1 is serine/threonine kinase and one of the polo-like kinase family members. Plk1 structurally has two functional domains; one is polo-box domain on C-terminal for targeting of substrate and involving in its subcellular localization (4), and the other is kinase domain regulated through phosphorylation by upstream kinases (5,6). The expression of Plk1 begins to increase from S/G2 phase, and its activity peaks at mitosis. Plk1 functions in various mitotic events such as centrosome maturation, assembly of the bipolar spindle, chromosome segregation, activation of the anaphase promoting complex (APC/C) and cytokinesis (3,7,8). Excessive or deregulated expression of Plk1 accelerates cell division abnormally and promotes tumorigenesis. Hence, Plk1 is usually over-expressed in various types of cancers (9), suggesting that Plk1 is considered as one of the strong candidate targets for anticancer therapy (10). As well as mitotic roles, it has been reported that Plk1 involves in checkpoint activation and recovery in response to DNA damage (11), even this mechanism has poorly been understood so far. In this review, we focus on the involvement of Plk1 in interphasic and mitotic DNA damage response. In addition, we refer to the relationship between Plk1 and p53 during DNA damage response.

DNA DAMAGE RESPONSE (DDR) DURING CELL CYCLE

Cells are continuously threatened with DNA damage by either endogenous reasons including by-product of metabolic pathway and replication stresses, or exogenous factor such as exposure to UV irradiation or genotoxic reagents. If DNA damage is allowed continuously, cells lose their own functions and could be developed to cancer (12). Fortunately, repair mechanisms have been evolutionally conserved and well-established for preservation of genetic stability under constantly being attacked conditions. Once DNA double strands are broken, it can be repaired using two types of DNA repair mechanisms, non-homologous end-joining (NHEJ) and homologous recombination (HR) (13). During NHEJ, two broken ends of DNA templates are simply re-connected. However, NHEJ is prone to change total DNA integrity and to induce genomic error by ligation of incongruence DNA ends (14). When NHEJ is inevitably operated in response to DNA double strand breaks (DSBs), at first, DNA lesion sites are recognized by Ku70 and Ku80 sensor proteins for NHEJ repair mechanism (15). Then, DNA-protein kinase (DNA-PK) is recruited on impaired DNA site by interaction with the activated Ku proteins (16). DNA-PK is one of the PIKK family members. ATM (ataxia talangectasia mutated) and ATR (ATM and RAD3-related), the key protein kinases in response to DNA damage, belong to this family (17) and is mentioned below. Once DNA-PK is located on the DSB region, it phosphorylates the effector proteins, especially multimeric complex (DNA ligase IV-XRCC4-XLF) to connect two ends of broken DNA (18). The other mechanism in response to DSB is HR which is restricted to S and G2 phase. Unlike NHEJ, HR repair pathway needs undamaged DNA template, and sister chromatid is used to repair by HR as a template (19). Broken DNA ends are recognized and bounded by Mre11-Rad51-Nbs1 (MRN) complexes (20). ATM kinase is then loaded on DNA lesion site and its activity is increased by interaction with the recruited MRN complexes. Subsequently, a large number of downstream target substrates such as Chk1/Chk2 are phosphorylated by the ATM. Activated ATM in the defected DNA regions can also phosphorylate γ-H2AX (21), and then Mdc1 is collected on the damaged site by γ-H2AX (22) and can amplify the γ-H2AX signals and form foci on the DSB regions (23). In the DSB foci, 5’ ends of two broken DNA are separated (24) by nucleases such as Mre11, Exo1, CtIP and BLM helicase (25,26). Exposed single strand DNA is then rapidly coated by RPA proteins (replication protein A) (27,28). In addition to ATM signals, ATR kinase signal pathway is also activated by ssDNA produced from 5’ ends (29). Following resection, RPA binding to ssDNA is replaced by Rad51 recombinase (30). Rad51 recruited on a damaged DNA combines the sister chromatid as an undamaged DNA template for recombination repair mechanism (31). During the previously mentioned repair mechanisms, cells containing defective genome should be stopped in progressing to the next stage of the cell cycle. For this, when DNA damages were perceived, surveillance mechanisms called checkpoints are activated. G1/S boundary checkpoint inspects the DNA integrity for blockage before the replication of the damaged DNA (32). If there are defects on DNA at G1 phase, CDK2 is inactivated by ATM/Chk2 signaling, but not by ATR/Chk1. Also, interaction with p21, a downstream target of p53, results from the suppression of the S-phase entry. During intra-S checkpoint, Cdc25 phosphatases are predominantly regulated by ATR/Chk1 signaling (33). G2/M checkpoint supervises the genome integrity before the segregation of chromosomes in mitosis. For mitosis progression after damage recovery, cyclinB/CDK1 is up-regulated and activated (34). Under this DNA damage response, Plk1, consistently activated during mitosis, is known as a direct or an indirect regulator of the cell cycle-dependent proteins including cyclinB, CDK1, and Cdc25 phosphatases (3).

PLK1 AND DNA DAMAGE RESPONSE IN S/G2 INTERPHASE

Before mitotic entry, Aurora A cooperating with Bora phosphorylates threonine 210 residues of Plk1. This residue in inactive Plk1 is located inside of a closed structure by interacting with its own polo-box domain. The closed structure of Plk1, however, is opened by Bora, and is exposed for this residue to be phosphorylated by Aurora A for the activation of Plk1 during mitotic entry (35). When cells are attacked by DNA damage, especially in G2 phase, cells do not progress into mitosis to block the abnormal chromosomes thereafter. Usually, Plk1 loses its activity in response to DNA damage and cell division is arrested by G2 DNA damage checkpoint activity. ATM/ATR directly phosphorylates Bora at threonine 501 residue when the DSB is induced by UV irradiation. Phosphorylated Bora is recognized and degraded by E3 ubiquitin ligase SCF-β-TRCP (36). Threonine 501 of Bora is not phosphorylated in due to DNA damage by the UV irradiation when the ATR is down-regulated. Indeed, when the phosphorylation-defective mutant of Bora (T501A) is overexpressed in cells with UV irradiation, Bora cannot interact with SCF-β-TRCP and is not degraded (36). Once Bora is destructed, Plk1 cannot be activated and cell cycle is arrested in the G2 phase. Mitotic entry is also restricted by Cdk1/cyclinB inhibition resulting from Plk1 inactivation. In addition, Cdc25 phosphatase is inhibited by Chk1 and Chk2, resulting in the inactivation of Cdk1 by preventing elimination of inhibitory phosphorylation at tyrosine 14 and 15. Once damaged DNA is restored, Cdc25 is recovered by activated Plk1, following the approval of mitotic entry (37). Chk1 is one of the downstream target proteins of Claspin, an adaptor protein of ATR under damaged DNA (38). When DNA damage is recovered, activated Plk1 phosphorylates Claspin, and such phosphorylation induces ubiquitin-dependent degradation of Claspin and allows the dissociation from ATR. Finally, checkpoint pathway is terminated and cells enter into mitosis (39) (Fig. 1).
Fig. 1.

Plk1 and DNA damage response in S/G2 phase.

Interestingly, it has been reported that Plk1 directly phosphorylates the Rad51 recombinase and facilitates the homologous recombination (HR). In this mechanism, sensor protein Rad51 in response to DSB is phosphorylated at serine 14 residue, and sequentially threonine 13 residue of Rad51 is phosphorylated by Casein kinase 2 (CK2). These phosphorylations facilitate the HR repair mechanism by increased interaction with Nbs1 (40). However, it still remains questionable how Plk1 is activated through what signal in response to DSB, because Plk1 is originally inactivated in the S/G2-phase.

DNA DAMAGE RESPONSE ASSOCIATED WITH PLK1 IN MITOSIS

Although mitosis is a very short period than other stages of cell cycle, it is a crucial phase because chromosome replicated during S phase is separated and genetic information is inherited to the daughter cells. The occurrence of DNA damage during mitosis might induce mitotic arrest in the general concept of the checkpoint to avoid generating abnormal daughter cells containing aneuploidy or mitotic catastrophe. The studies about DNA damage response in mitosis suggest that cells containing DNA damage caused by exposure to irradiation in various stages of mitosis show the same phenotypic effects with non-irradiated cells (41). In addition, it has been reported that DNA damage response seems to be absent or is not effectively activated in irradiated mitotic cells (41,42). However, although these cells continually progress through cell division process, the positive γ-H2AX signal known as a DNA break marker still exists, and apparent delay is observed under this condition. Subsequent finding reveals that mitotic progression of these cells is delayed during metaphase by spindle assembly checkpoint, when cells incur severe DNA damage by irradiation or damaging agent (11,43). What has become of Plk1 under this situation? Whereas Plk1 activity should be increased for recovery from G2/M transition checkpoint, it might be principally suppressed by DNA damage occurring during mitotic phase where Plk1 is already activated. After the induction of DNA damage, the kinase activity of Plk1 is down- regulated through ATM/ATR-dependent fashion (44-47). Inactivation of Plk1 during the mitotic DNA damage response occurs by the dephosphorylation of phosphor-threonine 210, a requirement for protein phosphatase 2A activity. ATM-/- and Chk1-/- cells with mitotic DNA damage show a clear rescue of Plk1 dephosphorylation, and the addition of caffeine also completely rescues this effect, suggesting that protein phosphatase 2A activity on Plk1 dephophorylation is dependent on ATM-Chk1 pathway in mitotic DNA damage response (44,45) (Fig. 2). Importantly, overexpression of phospho-mimic mutant of Plk1, T210D, overcomes the arrest induced by the DNA damage (11). These reports suggest that Plk1 plays the roles in the communication between the DNA damage and proper checkpoint. It also suggests that down regulation of Plk1 is necessary for arresting cell cycle to allow ample time for DNA repair and maintenance of genome stability during mitotic DNA damage response. Very severe DNA damage is induced to bypass both late mitotic process and cytokinesis over a short delay of transition between metaphase and anaphase, in spite of the suppression of Plk1 activity from the results of time lapse microscopy and FACS analysis (48). After then, cells contain 4N DNA contents, even though cells have positive γ-H2AX signal. The condensed chromosome becomes loose and the nucleus size is increased comparably to that of G2 phase (45). In addition, the inhibitory phosphorylation of Cdk1 and the G2-specific phosphorylation of Cdc25C are increased without a remarkable effects on cyclin B levels under this condition (44), insisting that cells containing mitotic DNA damage enter into G2-like G1 phase with 4N DNA contents. Subsequently, within 24 hours, these cells containing 4N DNA contents become 8N DNA cells by re-replication process called as endoreplication. Finally, cells are removed by apoptotic cell death after one cycle of replication (48). Polyploidy and aneuploidy are common phenomena in cancer cells, and a thorough understanding of endoreplication in mitotic DNA damage response may provide important insights for cancer biology (49).
Fig. 2.

Plk1 and DNA damage response in mitosis.

RELATIONSHIP BETWEEN PLK1 AND P53 IN DNA DAMAGE RESPONSE

Tumor suppressor p53 is a key tumor suppressor and functions as genome guardian through the induction of cell cycle arrest, apoptosis and senescence in various stress signals (50,51). When stresses such as DNA damage are exerted to the cell, p53 is stabilized for its activation phosphorylation at Ser15 and Ser20 by ATM/ATR and Chk1/Chk2, respectively (52-55). The accumulation of phosphor-p53 protein occurs by suppression of the interaction between p53 and MDM2, which stimulates ubiquitin-mediated degradation of p53 (56). p53 up-regulates its downstream protein such as p21/waf1 inhibiting CDKs, Gadd14 and 14-3-3, and induces DNA damage checkpoint regulating downstream proteins (57). The tumor suppressor activity of p53 in most human cancer cells is impaired by either its mutation or inactivation of p53 signaling. As almost 95% mutation of p53 is detectable in central regions encoding for the DNA binding domain, p53 mutants lose the ability for sequence specific transactivation (51). Cells where p53 is mutated or deleted do not arrest even in a damaged condition and cell division cycle with damages is progressed (58,59). They can also promote tumorigenesis at high frequency in mice and human (60,61). The roles of p53 inducing cell cycle arrest rivals with Plk1 functions which promotes the progression of the cell cycle. Plk1 is inhibitied by ATM/ATR dependent fashion after DNA damage (11,44), and is transcriptionally regulated either directly or indirectly by p53 (62-64). It localizes to the Plk1 promoter and binds to E2F1 which induces an increment of transcriptional level of Plk1. Its binding forms p53-E2F1-Plk1 promoter DNA complex and suppresses the expression of Plk1 (62). Furthermore, the expression of Plk1 is indirectly repressed by p53 through either targeting a sequence of CDE/CHR within Plk1 promoter by p21/waf1 or a negative regulation of FoxM1 (forhead box M1), which stimulates Plk1 expression caused by p53 (63,64). Therefore, cells prevent abnormal overcoming of cell cycle arrest by suppressing Plk1 through p53 during DNA damage repair. If DNA damage is not repaired completely, cell cycle is arrested consistently and finally cells undergo to death. In contrast, cells normally progress to next stage according to progression of cell cycle again when DNA damage is repaired completely (65). This recovery process by stoppage of checkpoint, especially G2/M transition arrest, requires the Plk1 activity which is essential for mitosis initiation (66). When cell cycle is recovered, re-activated Plk1 directly interacts with sequence specific DNA binding domain within p53, in return it is suppressed own transcriptional activity as well as pro-apoptotic function (67). Furthermore, Plk1 involves indirectly in decrement of phosphorylation on serine 15 of p53 interrupting interaction with MDM2, and reduction of p53 activity and MDM2 mediated degradation are increased (68). This interaction between MDM2 and p53 also is stimulated through phosphorylation at serine 260 of MDM2 by Plk1 (69). Furthermore, Plk1 phosphorylates serine 718 of Topors (topoisomerase 1 binding protein) which has ubiquitin and SUMO-1 E3 ligase activity and promotes degradation of p53 through inducing interaction of between Topors and p53 (69). In addition, Plk1 induces p53 export from nucleus during cell cycle arrest through activation of GSTE1 (G2 and S phase expressed 1 protein) (70). These results explain that the harmony of Plk1 and p53 protects cells from various stresses and aberrantly persistant cell cycle arrest (Fig. 3).
Fig. 3.

Networks between p53 and Plk1 in DNA damage responses.

As mentioned above, Plk1 is a major regulator controlling cell cycle and deregulation of this kinase induces overriding checkpoint which leads genomic instability and promotes cell transformation and initiation of tumorigenesis (71). On the other hand, inhibition of Plk1 can induce cytotoxicity such as apoptosis and this effect is connected with cancer therapy. It has been reported that excessive expression of Plk1 is found in cancer cells (72), and that depletion of Plk1 does little or no affect to normal cells in comparison with cancer cells (73,74). Moreover, the cytotoxic effect such as suppression of proliferation and apoptosis resulting from depletion of Plk1 is increased in cancer cells which have a defective p53 (75,76). These indicate that Plk1 is a selective target for cancer therapy and p53 can be noticed as determiner of Plk1 inhibition effect in cancer cells. However, there are still arguments in relation between cytotoxic effect by Plk1 depletion and role of p53, and a number of studies have reported that inhibition of Plk1 induces similar cytotoxicity and sensitivity regardless of any type of cell or status of p53. Poloxin, a targeting inhibitor of polo-box domain, represses proliferation in primary/normal non-transformed cell as well as tumor (77). Another polo-box domain-targeting inhibitor, purpurogallin strongly induces apoptosis in normal rat kidney cells and NIH3T3 cells (78). BI2536, a Plk1 kinase inhibitor targeting kinase domain of Plk1 has been reported to suppress proliferation and to induce apoptosis in both normal cell and cancer cell lines (79). This efficacy is also shown regardless of p53 status in cells (80). A recent report by using p53+/+ and p53-/- cell lines also demonstrates that there is no obvious different cytotoxic response between cancer cells with and without functional p53 (81). Moreover, the arrest point in cell cycle by collaboration of Plk1 inhibition with status of p53 is not the same. While the p53 positive cells are arrested and undergo apoptosis at G1/S phase, the p53 negative cell is arrested at G2/M after the treatment of Plk1 inhibitor (81).

CONCLUSION

During the past 25 years after the discovery polo in Drosophila melanogaster, most of the studies on Plk1 have been focusing on its mitotic roles. Recently, accumulating evidences are opening a new era in Plk1 history beyond the traditional mitotic function. As well as DNA replication and chromosome/microtubule dynamics (82,83), Plk1 also plays a role in overall DNA damage response including DNA checkpoint activation, checkpoint maintenance, damage recovery and DNA repair. When DNA damage occurs in S/G2 phase before Plk1 activation, through ATM/ATR-Bora-SCF-β-TRCP ubiquitin ligase, Plk1 activation is blocked until the damage is repaired. When damaged DNA is repaired by HR mechanisms, Plk1 directly phosphorylates a sensor protein, Rad51 to increase the interaction with Nbs1, and finally the HR is activated. For recovery from DNA damage, Plk1 phosphorylates and induces the inhibition Claspin, which is necessary for Chk1 activation. In mitotic DNA damage after Plk1 activation, inactivation of Plk1 is induced by dephosphorylation through ATM-Chk1-PP2A pathway. The inactivation of Plk1 by dephosphoprylation beyond traditional degradation by anaphase-promoting complex is one more interesting subject of Plk1 study. Severe mitotic DNA damage causes continuous inactivation of Plk1 and other mitotic kinases, allowing cells to skip mitotic events and endoreplication. Additionally, Plk1 and p53 reciprocally regulate each other during DNA damage checkpoint activation and adaptation, and recovery process. Plk1 directly targets Topor and GSTE1 to down regulate p53. Most of all, new functions of Plk1 beyond mitotic roles are speculated by their potential substrates. Previously, Yaffe et al. (2007) reported that more than 600 proteins were identified as the interactome for polo box domain (84). Although much more detailed experiments are needed to validate these proteins, these are hints that Plk1 has various functions in DNA damage response and other cellular events beyond its mitotic functions.
  84 in total

1.  Modulation of p53 function in cellular regulation.

Authors:  E Appella
Journal:  Eur J Biochem       Date:  2001-05

2.  Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.

Authors:  Lyuben Tsvetkov; David F Stern
Journal:  Cell Cycle       Date:  2005-01-05       Impact factor: 4.534

3.  MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks.

Authors:  Manuel Stucki; Julie A Clapperton; Duaa Mohammad; Michael B Yaffe; Stephen J Smerdon; Stephen P Jackson
Journal:  Cell       Date:  2005-12-29       Impact factor: 41.582

Review 4.  The Li-Fraumeni syndrome: an inherited susceptibility to cancer.

Authors:  S C Evans; G Lozano
Journal:  Mol Med Today       Date:  1997-09

5.  Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.

Authors:  X Shawn Liu; Hongchang Li; Bing Song; Xiaoqi Liu
Journal:  EMBO Rep       Date:  2010-06-25       Impact factor: 8.807

6.  Polo-like kinase-1 is a target of the DNA damage checkpoint.

Authors:  V A Smits; R Klompmaker; L Arnaud; G Rijksen; E A Nigg; R H Medema
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

Review 7.  Polo-like kinases and oncogenesis.

Authors:  Frank Eckerdt; Juping Yuan; Klaus Strebhardt
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

8.  Role of DNA-PK in the cellular response to DNA double-strand breaks.

Authors:  Sandeep Burma; David J Chen
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

9.  Human exonuclease 1 and BLM helicase interact to resect DNA and initiate DNA repair.

Authors:  Amitabh V Nimonkar; A Zeynep Ozsoy; Jochen Genschel; Paul Modrich; Stephen C Kowalczykowski
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

10.  Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex.

Authors:  K E Adams; A L Medhurst; D A Dart; N D Lakin
Journal:  Oncogene       Date:  2006-02-13       Impact factor: 9.867

View more
  30 in total

1.  Aging and Protein Kinases.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Jade-1S phosphorylation induced by CK1α contributes to cell cycle progression.

Authors:  Lori Borgal; Markus M Rinschen; Claudia Dafinger; Valérie I Liebrecht; Hinrich Abken; Thomas Benzing; Bernhard Schermer
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.

Authors:  Takashi Takeshita; Mariko Asaoka; Eriko Katsuta; Sara J Photiadis; Sumana Narayanan; Li Yan; Kazuaki Takabe
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

4.  Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.

Authors:  Pang-Ning Teng; Nicholas W Bateman; Guisong Wang; Tracy Litzi; Brian E Blanton; Brian L Hood; Kelly A Conrads; Wei Ao; Kate E Oliver; Kathleen M Darcy; William P McGuire; Keren Paz; David Sidransky; Chad A Hamilton; G Larry Maxwell; Thomas P Conrads
Journal:  Hum Cell       Date:  2017-03-01       Impact factor: 4.174

5.  In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.

Authors:  Ileine M Sanchez; Timothy J Purwin; Inna Chervoneva; Dan A Erkes; Mai Q Nguyen; Michael A Davies; Katherine L Nathanson; Kristel Kemper; Daniel S Peeper; Andrew E Aplin
Journal:  Mol Cancer Ther       Date:  2019-07-03       Impact factor: 6.261

6.  RNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemia.

Authors:  Liang Tian; Juan Liu; Guo-Hua Xia; Bao-An Chen
Journal:  Med Oncol       Date:  2017-01-05       Impact factor: 3.064

7.  Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Authors:  Glen J Weiss; Gayle Jameson; Daniel D Von Hoff; Barbara Valsasina; Cristina Davite; Claudia Di Giulio; Francesco Fiorentini; Rachele Alzani; Patrizia Carpinelli; Alessandro Di Sanzo; Arturo Galvani; Antonella Isacchi; Ramesh K Ramanathan
Journal:  Invest New Drugs       Date:  2017-07-20       Impact factor: 3.850

8.  Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.

Authors:  Zhiguo Li; Jinghui Liu; Jie Li; Yifan Kong; George Sandusky; Xi Rao; Yunlong Liu; Jun Wan; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

Review 9.  Budding yeast Rad51: a paradigm for how phosphorylation and intrinsic structural disorder regulate homologous recombination and protein homeostasis.

Authors:  Tai-Ting Woo; Chi-Ning Chuang; Ting-Fang Wang
Journal:  Curr Genet       Date:  2021-01-12       Impact factor: 3.886

10.  A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.

Authors:  Dong Wang; Bethany Veo; Angela Pierce; Susan Fosmire; Krishna Madhavan; Ilango Balakrishnan; Andrew Donson; Irina Alimova; Kelly D Sullivan; Molishree Joshi; Mark Erlander; Maya Ridinger; Nicholas K Foreman; Sujatha Venkataraman; Rajeev Vibhakar
Journal:  Neuro Oncol       Date:  2022-03-12       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.